Auris Medical (EARS) Stock Price Down 6.9%

Auris Medical Holding AG (NASDAQ:EARS) shares were down 6.9% during mid-day trading on Tuesday . The company traded as low as $0.26 and last traded at $0.27. Approximately 1,297,221 shares changed hands during trading, an increase of 26% from the average daily volume of 1,032,271 shares. The stock had previously closed at $0.29.

Separately, ValuEngine upgraded shares of Auris Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of -14.04. The company has a market capitalization of $12.44, a PE ratio of -0.40 and a beta of 0.11.

Auris Medical (NASDAQ:EARS) last released its earnings results on Tuesday, November 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05.

A hedge fund recently bought a new stake in Auris Medical stock. Virtu KCG Holdings LLC purchased a new stake in Auris Medical Holding AG (NASDAQ:EARS) during the second quarter, according to its most recent filing with the SEC. The firm purchased 141,507 shares of the biotechnology company’s stock, valued at approximately $101,000. Virtu KCG Holdings LLC owned 0.32% of Auris Medical at the end of the most recent reporting period. 19.11% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at

Auris Medical Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with's FREE daily email newsletter.

Leave a Reply